Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: China’s healthcare reforms, a blessing or a threat?

Michael Custer, analyst at Solidiance in Shanghai, explains that healthcare service providers will come out on top from China’s healthcare reforms.

Until now, China’s healthcare system has served the rapidly developing country well. China impressively succeeded in its efforts to achieve universal healthcare coverage, bringing the insured rate up from 50% in 2005 to 95% by 2011. And, despite achieving universal coverage – a rarity for developing countries – the country has been able to keep costs relatively in check, spending just 5.5% of GDP on healthcare in 2014.

Two trends, however, are threatening the long-term sustainability of China’s system. First, China is experiencing a rapidly aging population. China’s old age dependency ratio, a reliable predictor of healthcare costs, will match that of modern day Japan by 2045.

Second, more of its population is becoming unhealthy. The rates of many chronic diseases as well as cancer are on the rise in China due to pollution, poor diet and unhealthy lifestyle choices. To put this in perspective, the diabetes rate in China is already higher than that of the US.

Without enforcing any reforms to the current system, these trends will lead to enormous strains on the government’s budget. According to Solidiance’s white paper titled “China Healthcare Reforms: Who Will Survive?”, it is projected that 20% of China’s government budget will be allocated to healthcare by 2045. That figure is nearly double what it is today, and behind only New Zealand and the United States.

Under more realistic scenarios, considering China’s growing health problems and an increased share in healthcare funded by the government, the share of state budget allocated towards healthcare will range from 24% to 33% – figures that are by far the largest in the world.

Without change, China’s current healthcare system will become unaffordable. The latest round of reforms, launched towards the end of 2015, are thus aimed at ensuring sustainability by reducing costs so as to create a more efficient healthcare system to its people.

For foreign medical device manufacturers and pharmaceutical companies, the reforms are especially worrisome, as the government is increasing the downward price pressure on both industries. The pharmaceutical industry, which makes up a much larger portion of healthcare spending in China than the device industry, is expected to feel the initial brunt of regulatory pressure.

Despite the reforms adding additional complexity, it is important to remember that China’s healthcare market is large and growing rapidly, with value projected to surpass US$1 trillion by 2020. With a market of that size, there are endless strategies that both foreign pharmaceutical and medical device companies can pursue to ensure a piece of the pie and capitalise on opportunities in China.

A key strategy suggested for multinational companies is to focus on developing and introducing new products. Innovative drugs and medical devices will continue to demand a premium in post-reform China. Additionally, maintaining the edge that foreign multinationals have in r&d and technology is crucial for future success as another emphasis of the reforms is to increase the technical capabilities of domestic healthcare companies, especially in the medical device sector.

Healthcare service providers, on the other hand, will benefit the most out of these reforms. China’s healthcare system is currently highly centralised. Chinese citizens tend to settle for level 3 public hospitals, widely regarded as the country’s best hospitals, to treat everything ranging from the common cold to cancer.  This results in over-utilisation of level 3 hospitals and under-utilisation of clinics, level 1, and level 2 hospitals. This centralisation and lack of efficiency within the public healthcare system is unsustainable and results in poor quality, especially in specialty medicine, and significantly higher costs for the government.

The ultimate goal of enforcing these reforms is to move the Chinese system towards a more decentralised model such as those employed in Europe. To do this, the government is aiming to administer a hierarchal system of healthcare, encourage the development and utilisation of private facilities, and develop a nationwide system of general practitioners. It is this supportive regulatory environment combined with a growing middle class that is beginning to demand better quality healthcare services that will continue to fuel the growth in the private healthcare industry, resulting in increased foreign investment in the healthcare service sector within China.

The Solidance white paper “China Healthcare Reforms: Who Will Survive?” can be downloaded here.

Posted on: 09/03/2017 UTC+08:00


News

First REIT, the SGX healthcare real estate investment trust owned by Indonesia’s Lippo Group, has reported a 0.9% rise in distribution per unit (DPU) of S$0.0214 for the third quarter of the year.
Metlifecare, New Zealand’s second-largest listed retirement village operator, plans to spend NZ$240 million (US$167.2 million) to develop a waterfront retirement village at Scott Point, in the Auckland suburb of Hobsonville.
Thonburi Healthcare Group, the country's third largest hospital operator, has inked an MoU with Korea’s Green Cross MS and Green Cross Laboratories.
At its annual general meeting at the end of last week, Gordon Ballantyne, new chief executive of Healthscope, Australia’s second largest private healthcare operator, said that he expected current private hospital market conditions to continue in the short term.
Hong Kong-listed healthcare company China Wah Yan Healthcare plans to consolidate its shares. The move has been pushed onto the company to comply with trading requirements.
Monash IVF Group, Australia’s second largest fertility treatment provider, has appointed David Morris as the CEO and managing director effective from 13 November. After eight years, James Thiedeman stepped down in May.
SGX-listed Singapore Medical Group, a multi-disciplinary specialist healthcare services provider has announced its latest acquisition.
Malaysia's Top Glove is on the acquisition trail. The world’s largest rubber glove manufacture has signed an MoU to buy all the ordinary shares of Eastern Press for M$47.25 million (US$11.18 million) in cash. Eastern Press is principally engaged as a printer and supplier of packaging material. It is also the major supplier of packaging material to Top Glove's subsidiaries in Malaysia.



Analysis

Is there a case to be made for a merger between Metlifecare and Summerset Group, New Zealand’s second and third-largest listed retirement village operators? First NZ Capital reckons so and analyst Arie Dekker makes an eloquent case for it in a new research note.
Stephenson Harwood’s Tom Platts, Ben Hickson and Su Wai Phyo report on key changes implemented by the Myanmar government to facilitate much-needed foreign investment in the country’s healthcare sector.
In the lead-up to the UN’s International Day of the Older Persons on 1 October, Jason Sadler, president, Cigna International Markets, looks at the impact of an aging population on the world’s healthcare system and the role that digital technology will play in meeting this new challenge.
By 2042 there will be more over-65s in Asia than the populations of the Eurozone and North America combined. We look at the business opportunities this creates.
Albert Wong argues that biomedical technology should not be ignored and explains how the Hong Kong Science and Technology Parks Corporation can support it.
Jacob Pope explains why medical tourism remains one of the region’s most significant industries.
APACMed’s Fredrik Nyberg looks at how local and multinational IVD companies are developing novel solutions for Asia’s unique needs.
It is perhaps a curious line in the sand to draw, but the new hospital in Dunedin, the second-largest city in the South Island of New Zealand, is gearing up to be a significant battle in the use of private-public partnership funding in the APAC region.


Civica

Podcasts

AON

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices